Beta2‐Adrenergic Stimulation Induces Resistance Training‐Like Adaptations in Human Skeletal Muscle: Potential Role of KLHL41
Open Access
- 4 October 2024
- journal article
- research article
- Published by Wiley in Scandinavian Journal of Medicine & Science in Sports
- Vol. 34 (10) , e14736
Abstract
Skeletal muscle mass plays a pivotal role in metabolic function, but conditions such as bed rest or injury often render resistance training impractical. The beta2‐adrenergic receptor has been highlighted as a potential target to promote muscle hypertrophy and treat atrophic conditions. Here, we investigate the proteomic changes associated with beta2‐adrenergic‐mediated muscle hypertrophy, using resistance training as a hypertrophic comparator. We utilize MS‐based proteomics to map skeletal muscle proteome remodeling in response to beta2‐adrenergic stimulation or resistance training as well as cell model validation. We report that beta2‐adrenergic stimulation mimics multiple features of resistance training in proteome‐wide remodeling, comprising systematic upregulation of ribosomal subunits and concomitant downregulation of mitochondrial proteins. Approximately 20% of proteins were regulated in both conditions, comprising proteins involved in steroid metabolism (AKR1C1, AKR1C2, AKRC1C3), protein‐folding (SERPINB1), and extracellular matrix organization (COL1A1, COL1A2). Among overall most significantly upregulated proteins were kelch‐like family members (KLHL) 40 and 41. In follow‐up experiments, we identify KLHL41 as having novel implications for beta2‐adrenergic‐mediated muscle hypertrophy. Treating C2C12 cells with beta2‐agonist for 96 h increased myotube diameter by 48% (p < 0.001). This anabolic effect was abolished by prior knockdown of KLHL41. Using siRNA, KLHL41 abundance was decreased by 60%, and the anabolic response to beta2‐agonist was diminished (+ 15%, i.e., greater in the presence of KLHL41, knock‐down × treatment: p = 0.004). In conclusion, protein‐wide remodeling induced by beta2‐adrenergic stimulation mimics multiple features of resistance training, and thus the beta2‐adrenergic receptor may be a target with therapeutic potential in the treatment of muscle wasting conditions without imposing mechanical load.Keywords
Funding Information
- Team Danmark
- Novo Nordisk Fonden
This publication has 44 references indexed in Scilit:
- Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseasesCellular and Molecular Life Sciences, 2022
- Chronic treatment with terbutaline increases glucose and oleic acid oxidation and protein synthesis in cultured human myotubesCurrent Research in Pharmacology and Drug Discovery, 2021
- Treatment with a β-2-adrenoceptor agonist stimulates glucose uptake in skeletal muscle and improves glucose homeostasis, insulin resistance and hepatic steatosis in mice with diet-induced obesityDiabetologia, 2020
- Anabolic and lipolytic actions of beta2‐agonists in humans and antidoping challengesDrug Testing and Analysis, 2020
- Biology of Hsp47 (Serpin H1), a collagen-specific molecular chaperoneSeminars in Cell & Developmental Biology, 2017
- Functional Dynamics within the Human Ribosome Regulate the Rate of Active Protein SynthesisMolecular Cell, 2015
- Muscle as a “Mediator” of Systemic MetabolismCell Metabolism, 2015
- Identification of KLHL41 Mutations Implicates BTB-Kelch-Mediated Ubiquitination as an Alternate Pathway to Myofibrillar Disruption in Nemaline MyopathyThe American Journal of Human Genetics, 2013
- The potential and the pitfalls of β-adrenoceptor agonists for the management of skeletal muscle wastingPharmacology & Therapeutics, 2008
- Clenbuterol-induced fiber type transition in the soleus of adult ratsEuropean Journal of Applied Physiology, 1996